Multiple applications of genome editing by CRISPR-Cas9 necessitate stringent regulation and Cas9 variants have accordingly been generated whose activity responds to small ligands, temperature or light. However, these approaches are often impracticable, for example in clinical therapeutic genome editing in situ or gene drives in which environmentally-compatible control is paramount. With this in mind, we have developed heritable Cas9mediated mammalian genome editing that is acutely controlled by the cheap lysine derivative, Lys(Boc) (BOC). Genetic code expansion permitted nonphysiological BOC incorporation such that Cas9 (Cas9 BOC ) was expressed in a full-length, active form in cultured somatic cells only after BOC exposure. Stringently BOC-dependent, heritable editing of transgenic and native genomic loci occurred when Cas9 BOC was expressed at the onset of mouse embryonic development from cRNA or Cas9 BOC transgenic females. The tightly controlled Cas9 editing system reported here promises to have broad applications and is a first step towards purposed, spatiotemporal gene drive regulation over large geographical ranges.
Introduction
Many applications of genome editing by CRISPR-Cas9 (1) (2) (3) (4) would benefit from being tightly controllable to minimize unintended, potentially harmful genome cleavage due to leaky nuclease activity. Such regulation would likely impact multiple contexts, including restricting genome editing to given anatomical sites in clinical somatic cell gene therapy (5, 6) and gene drives (4, 7) . Gene drives duplicate a segment of genomic DNA in vivo independently of selection and in principle work in any sexually reproducing species so that all offspring inherit the gene drive segment (7) . Given their speed and efficiency, gene drives have the potential to accelerate the dissemination of beneficial genetics in insects, crops and animals; they might streamline the introduction of homozygous mutations to study recessive alleles, eliminate destructive invasive species and agricultural pests, or to improve livestock rapidly and cheaply (for example, to prevent disease transmission), eliminating the need for protracted breeding programs (4) . Recently, exceptionally high rates of gene drive transmission based on CRISPR-Cas9 genome editing were demonstrated in flying insect populations (8, 9) . However this remarkable efficiency mandates remarkable control.
Previous methods to control Cas9 activity (reviewed in Ref. 10 ) have involved modulating light (11) (12) (13) or temperature (13, 14) , but these approaches are difficult to regulate where barriers exist to light penetration (eg in larger organoids in vitro or environmentally) and are limited under conditions of temperature homeostasis (eg in mammals). Small molecule effectors including rapamycin, trimethoprim and (Z)-4-hydroxytamoxifen have also been used to control Cas9 activity in which, although each system differs, in general a domain is fused to Cas9 such that effector binding activates Cas9 through formation of functional protein (15) (16) (17) , protein conformational change (18) or translocation into the nucleus (19) .
However, these approaches often suffer from high background activities (16, 18, 19) . For instance, a rapamycin-inducible system of gene activation caused a ~10-fold target increase in the absence of rapamycin (16) and the original demonstration of Cas9 switching by conformational change exhibited background editing of ~10%; refinement to reduce the background significantly reduced on-target editing (18) . Moreover, rapamycin and trimethoprim are antibiotics with the potential to alter the microbiome, and as potential drivers of antimicrobial resistance, their deployment is likely to be problematic. (Z)-4-Hydroxytamoxifen, which is the major active metabolite of the anticancer agent, tamoxifen, is an antagonist of the estrogen receptor, hemolytic towards human erythrocytes, an endocrine disruptor and aquatic toxin (20) (21) (22) . The cost of small molecule regulators in financial and environmental terms is also likely to be prohibitive on large scales.
Clearly, Cas9 regulation by other means will be advantageous or essential for many of its potential applications. To address this, we considered that a cheap amino acid such as the lysine derivative, H-Lys(Boc)-OH (BOC), might be harnessed for Cas9 control. BOC can be incorporated into proteins of interest by genetic code expansion (23) , suggesting that a novel tier of regulating Cas9 might be achieved by generating a functional Cas9 variant whose expression (translation) and activity depended on the presence (incorporation during translation) of BOC. We therefore set out to evaluate the control of Cas9 by genetic code expansion in mammalian heritable genome alteration as a first step to the stringent control of gene drives and other applications.
Results
Establishing genetic code expansion in mouse embryos. As a starting point, we characterized genetic code expansion to control eGFP expression in transgenic mouse embryos. To this end, an orthogonal pyrrolysyl-tRNA synthetase/tRNA (PylRS/Pyl tRNA) pair was selected to direct incorporation of BOC into an amber stop codon at position 150 of eGFP, giving eGFP N150B (24) ; we anticipated that in this system, translation of eGFP N150B would be terminated prematurely (at codon 150) in the absence of BOC and functional eGFP N150B protein produced only following BOC exposure ( Figure 1A -D). Because we were interested in modulating protein activity in a mouse model, we designed an eGFP N150B transgene to express each of the components required for ubiquitous, constitutive expression of the eGFP N150B system (PylRS, Pyl tRNA and eGFP N150B ; Supplementary Figure S1A ) and coinjected it with wild-type (wt) mouse B6D2F1 sperm into B6D2F1 metaphase II (mII) oocytes (Supplementary Figure S1B ). This method of transgenesis by intracytoplasmic sperm injection (ICSI) typically yields >80% of transgene-expressing preimplantation embryos after ~4 days of development (E3.5) (25, 26) . Following eGFP N150B transgene injection, some of the resultant embryos (28.9%; n=44) clearly fluoresced after 4 days of culture in media supplemented with 10 mM BOC for the final 24 h, but only ~2% fluoresced (with a weak or partial signal; n=46) when BOC was omitted (p<0.001; Supplementary Figure S1C,D). This suggested that the orthogonal system could enable BOC-inducible eGFP N150B expression in embryos. To enhance spatiotemporally regulated embryonic expression, we synthesized all RNA components of the BOC system (ie PylRS cRNA, eGFP N150B cRNA and Pyl tRNA) in vitro and coinjected them into B6D2F1 mII oocytes followed by exposure to different concentrations of BOC (Supplementary Figure   S2A ). These injections were analogous to eGFP N150B transgenesis (Supplementary Figure   S1A ,B) except that RNA was delivered directly rather than relying on transcription of transgene DNA. All injected oocytes continually exposed to 1 mM BOC expressed readilydetectable green fluorescence (ie eGFP N150B ) after 5 and 24 h (Supplementary Figure S2B -D). Thus, RNA injection resulted in efficient BOC-inducible eGFP N150B expression in oocytes, paving the way for its application to other proteins.
Genetic code expansion enables regulation of Cas9 activity via an orthogonal
amino acid in tissue culture. We wished to evaluate whether genetic code expansion could be harnessed so that the RNA-guided nuclease activity of Cas9 (1, 2, 27) could be controlled by adding BOC. Since Cas9 residues can be substituted with a bulky Lys derivative without abolishing endonuclease activity (11), we tested Cas9 in which K510 or K742 were replaced with BOC residues. To evaluate this system, HEK293 cells were first transfected with constructs encoding eGFP gRNA, eGFP fused to a destabilization domain (eGFP-DD) (28) , Pyl tRNA, PylRS and Cas9 K510B , Cas9 K742B or Cas9 K510B,K742B .
Transfectants exposed to BOC expressed Cas9 mutants accompanied by a marked reduction of eGFP protein levels, suggestive of BOC-induced Cas9 K510B eGFP gene targeting activity ( Figure 2A ). Cas9 K510B activity was induced by BOC in the micromolar range in a dosedependent manner ( Figure 2B , n=3) and Cas9 K510B disappearance post-induction was accelerated when it was fused to the destabilization domain (Cas9 K510B -DD in Figure 2C ,D;
p=0.002, n=3). We accordingly evaluated induction of Cas9 mutant activity by BOC in early embryos.
BOC-switchable endogenous transgene editing in one-cell embryos. Oocytes
were coinjected with Pyl tRNA and cRNAs encoding PylRS and Cas9 K510B , Cas9 K742B or Cas9 K510B,K742B , incubated for 4~5 h to allow cRNA-encoded protein expression (29) and then coinjected with eGFP gRNA plus sperm (30) from males homozygous for a ubiquitously-expressed single-copy eGFP transgene (31) previously produced by us ( Figure   3A ). Mutant Cas9 protein expression was enabled by exposure to BOC immediately after RNA injection for 4~5 or 24 h ( Figure 3A ). In these experiments (with Cas9 K510B unless stated otherwise), intracytoplasmic sperm injection (ICSI) was expected to produce embryos that fluoresced unless the eGFP gene had successfully been inactivated by editing (3) . As anticipated, control embryos lacking one or more of the BOC system components all contained brightly fluorescent blastomeres because editing had not taken place and the paternal (sperm-derived) eGFP transgene was therefore expressed ( Figure 3B ,C). By contrast, when all BOC components were present and embryos exposed to 1 mM BOC, bright fluorescence was eliminated ( Figure 3B ,C). This clearly indicated that the eGFP gene had been inactivated with a high efficiency. Development to the blastocyst stage was reduced following 1 mM BOC exposure for 24 h but it was more efficient following briefer (4~5 h) BOC exposure ( Figure 3D ). eGFP mRNAs were intact in fluorescing blastocysts (n=12) but in all tested non-fluorescing blastocysts, sequencing revealed that transcripts corresponding to eGFP contained one or more mutations corresponding to the targeted region (n=8; Supplementary Figure S4A ). Analogous experiments with cRNA encoding a different Cas9 BOC mutant, Cas9 K742B , followed by 4~5 h BOC exposure also efficiently yielded non-fluorescing blastocysts (n=38; Figure 3E ). Induced editing in the system also worked with the double mutant, Cas9 K510B,K742B (n=24), albeit less efficiently; 97.4% for Cas9 K742B ( Figure 3E ) vs 50.0% for the double mutant ( Figure 3F ). These data show that BOC system component levels compatible with embryo development induced efficient editing by Cas9 K510B and Cas9 K742B . Furthermore, the developmental read-out clearly demonstrates that any truncated Cas9 protein produced in the absence of BOC, or pantranscriptomic amber-codon read-through of endogenous mRNAs during BOC treatment, had limited cytotoxicity, because even though mouse preimplantation embryos are exquisitely sensitive to developmental perturbation, it did not prevent high rates of development. Moreover, editing was absolutely BOC-dependent, showing that in these experiments the system exhibited little, if any, leakiness.
Heritable, BOC-dependent transgene editing. We next assessed editing heritability in the BOC-inducible system by performing a Cas9 K510B series in which Pyl tRNA-and cRNA-injected oocytes were immediately cultured in 1 mM BOC for 4~5 h, injected with eGFP gRNA plus eGFP + sperm ( Figure 3A ) and the resulting 2-cell embryos nonselectively transferred to surrogate mothers. When injection of RNA system components and/or exposure to BOC were omitted, the resulting control offspring fluoresced green ( Figure 4A ,B), which was expected given that an intact eGFP allele was present in all fertilizing sperm. However, only 1/18 (5.6%) of pups derived from test embryos following BOC induction were fluorescent, suggestive of efficient editing ( Figure 4A Figure 4C ). Although individuals typically contained a mixture of edited eGFP sequences consistent with mosaicism, we did not detect a mixture of fluorescence and non-fluorescence in offspring, suggesting that editing had occurred efficiently at the 1-cell stage. These data suggest that BOC had efficiently induced, and was a stringent requirement for, Cas9 K510B genome editing activity and that the extent of editing in preimplantation embryos provided an accurate meter of editing in offspring.
BOC-dependent heritable editing of native alleles. We next determined whether,
in an analogous protocol, BOC could induce Cas9 K510B -mediated editing of native alleles of the mouse strain, B6. To this end, we selected genes encoding the testis-determining factor, Sry (32), or tyrosinase (Tyr), which confers dark fur pigmentation in B6 mice (33) .
Targeting Sry with control Cas9 (lacking a BOC codon) and a mixture of two gRNAs ( Supplementary Table S1 ) yielded 16 females of which five (31.3%) carried Sry harboring a mutation, implying that Sry inactivation had resulted in sex reversal. When we employed Cas9 K510B in the absence of BOC, 0/7 of the resulting females carried Sry, but when BOC was included, 2/10 (20.0%) females were Sry-positive ( Figure 5A ) and in both cases Sry had undergone frame-shifting edits (Supplementary Figure S4B ). Editing the coat-color determinant, Tyr by control Cas9 and three gRNAs ( Supplementary Table S1 ) had previously resulted in 92.9% (n=14) of offspring with altered coat-color phenotypes (34) .
A similar efficiency (93.3%; n=15) of Tyr editing was achieved by BOC-dependent Cas9 K510B -mediated targeting ( Figure 5B ,C); sequence analysis of coat-color mutants (n=6) revealed that all contained one or more frame-shifting Tyr gene indels in the targeted region (Supplementary Figure S4C ) with a pattern of sequence mosaicism analogous to those observed for eGFP editing (Supplementary Figure S4A ). This suggests that BOCinduced editing of endogenous loci by Cas9 K510B occurred at comparably high efficiencies to editing mediated by control Cas9.
Inducible genome editing via Cas9 BOC supplied by a mouse transgenic line.
We extended this principle to evaluate BOC-induced editing by Cas9 K510B driven in transgenic mice by the ZP3 promoter, pZP3, which is uniquely expressed in growing oocytes and has become a classical driver of transgene expression in the maternal germline (35, 36) . Comparison of expression between pZP3-Cas9 and pZP3-Cas9 K510B transgenic lines is confounded by the differing sites of transgene integration in each, but within each line we noted a marked decline in expression in hemizygotes (containing a single transgene allele) from germinal vesicle stage oocytes, such that pZP3 transgene mRNA was not detectable in mature, fertilizable mII oocytes of the type used in ICSI ( Figure 6A ). Thus, the levels of transgene-encoded Cas9 and Cas9 K510B transcripts were extremely low.
When mII oocytes from pZP3-Cas9 hemizygous transgenic females were injected with eGFP + sperm plus gRNA targeting eGFP (but no Cas9 cRNA), 21.2±6.9% of the resulting blastocysts (n=96) underwent editing as judged by loss of fluorescence ( Figure 6B ); editing was confirmed by sequencing (Supplementary Figure S4D ). Genome editing had therefore been mediated by endogenous transgene-encoded Cas9 in mII oocytes from hemizygous transgenic females.
We next evaluated whether this might be extended to a BOC-inducible system by injecting mII oocytes from pZP3-Cas9 K510B Figure 6B ). Given that the control editing rate was 21.2% (see above), BOCdependent editing by Cas9 K510B transgene-expressing females had therefore occurred at ~34.9% of the control rate (7.4% for Cas9 K510B vs 21.2% for the control; Figure 6B ).
Discussion
This work demonstrates controllable, heritable genome editing in mouse embryos by inducing Cas9 activity with the cheap, non-physiological (in mammals) amino acid, Lys(Boc) (BOC) via genetic code expansion. Genetic code expansion has previously been employed for the incorporation of non-physiological amino acids other than BOC, always into the bystander reporter protein, GFP in vivo (37) (38) (39) . We here demonstrate that the BOC system applied to Cas9 is compatible with efficient full-term development even when it is active at an early and exquisitely sensitive phase of embryogenesis. This not only provides a developmental indication of limited or surmountable toxicity due to broad genomic amber codon read-through (at least when it occurs during early mammalian embryogenesis) but argues against extensive off-target editing in the system (40) . In contrast to the higher background activities or restricted applicability of many switchable systems (11) (12) (13) 16, 18, 19) , this work accordingly demonstrates low or zero Cas9 BOC activity in the absence of BOC; without BOC, Cas9 BOC activity was undetectable under the conditions of these experiments, suggesting that the system was subject to little, if any, leakiness.
The BOC-inducible principle should also apply to modified Cas9 activities such as (44, 45) .
BOC-inducible Cas9 in gametes or embryos near the time of fertilization also promises to mediate tight gene drive regulation. Although potentially powerful, gene drives may have unforeseen and uncontrollable consequences (4). The Cas9 system described here addresses this, and because BOC is a cheap amino acid, it could potentially be used environmentally to control gene drive expression. We generally used 1 mM BOC, but even in a non-optimized in vitro system, a 1,000-fold lower BOC concentration worked detectably ( Figure 2B ). Lower concentrations are expected to exert fewer co-lateral effects and reduce costs. Thus, BOC (or something analogous) promises to enable gene-drive activity that can be controlled over large geographic ranges, in principle restricting them to areas of BOC exposure. Gene-drive switchability will also reduce the emergence of resistance by periodically removing the selectable advantage of gene drive neutralization;
once the gene drive is inactive, it cannot be selected against. There is no reason a priori why this approach should be limited to editing by Cas9, and other nuclease frameworks (eg Cpf1) should be amenable to analogous regulation.
In addition, genome editing is non-trivial in large animals, whose importance in the provision of biomedical models and clinical reagents (eg for xenotransplantation) is increasing (46) . By streamlining safe target locus homogenotization (ie allelic replacement 
Materials and Methods
Plasmid construction. Plasmid pEF1α-FLAG-PylRS-IRES-Neo-4xU6-PylT U25C (a kind gift from Dr. Jason Chin) was used for the expression of pyrrolysyl-tRNA synthetase and pyrrolysyl tRNA CUA and to direct the incorporation of BOC. Plasmid pCAG-eGFP has been described previously (25) . Plasmids p3s-Cas9HC (Addgene plasmid #43945) and
pU6-gRNA-GFP(5-10) were generous gifts respectively from Dr. Jin-Soo Kim and Prof.
Anton Wutz; pU6-gRNA-GFP(5-10) expresses a gRNA targeting eGFP corresponding to the region between codons 5 and 10. We generated pCAG-eGFP N150B using pCAG-eGFP as template in a PCR reaction with primers F1 and R1 (primer sequences are given in Table   S1 ) to replace the N150 codon of eGFP with TAG (a B codon), as verified by sequencing with primers S1 and S2. To construct pCAG-eGFP-DD (encoding eGFP T308D,S473D ), a 906 base pair (bp) fragment containing eGFP-DD (GeneArt, Regensburg, Germany) was introduced by Gibson assembly into EcoRI-digested pCAG-eGFP and verified by sequencing with primers S1 and S2.
To generate pEF1α-FLAG-PylRS-CAG-eGFP(150TAG)-4xU6-PylT U25C (designated SP44), the 8,286 bp BamHI-SalGI fragment of pEF1α-FLAG-PylRS-IRES-Neo-4xU6-PylT U25C was joined by Gibson assembly to a 2,748 bp CAG-eGFP N150B PCR amplimer generated with primers F4 and R4 from pCAG-eGFP N150B and confirmed by sequencing with primers S1, S2 and S4. To construct plasmid p3s-Cas9HC K510B (SP81), Gibson assembly was used to join the 5,862 bp KpnI-BsrGI fragment from p3s-Cas9HC to a PCR amplimer from p3s-Cas9HC containing Cas9 in which the codon for K510 had been replaced by TAG (B) using primers F5 and R5. The sequence of p3s-Cas9HC K510B was verified by sequencing with primers S5, S6 and S7. To construct plasmid p3s-Cas9HC K742B (SP82), the 6152 bp PmlI-BsrGI fragment from p3s-Cas9HC was joined by Gibson assembly to a PCR amplimer from p3s-Cas9HC containing Cas9(514-745) (SP116) in which the codon for K742 had been replaced by TAG (B) using primers F6 and R6. The sequence of p3s-Cas9HC K510B was verified by sequencing with primers S7, S8 and S9. Construct pU6-gRNA-GFP(51-56) was prepared from pU6-gRNA-GFP(5-10) and its sequence confirmed with primers S16 and S17. Plasmid pEF1α-FLAG- Target gRNA synthesis. Target gRNAs were produced as previously described (49) .
PylRS
Briefly, T7-gRNA-scaffold products were amplified by PCR using Pfx polymerase week-old males were prepared as described previously (3, 30, 31) . Sperm were resuspended in ice-cold nuclear isolation medium (NIM; ~0.5 ml per epididymis) and stored on ice or at 4 °C. Immediately prior to injection, ~50 μl of freshly-prepared sperm suspension was containing a single sperm head was injected (ICSI) within ~60 min of DNA/gRNA mixing into mII oocytes held in droplets of M2 under mineral oil, essentially as described (25, 30, 31) . Where indicated, mII oocytes that had been injected with RNA were injected with sperm heads (ICSI) 3~4 h later.
Synthesis of RNA in vitro and microinjection into mII oocytes.
The preparation of 5'-capped and polyadenylated in vitro transcripts was from cRNA synthesized from linearized plasmid template DNA in a T7 mScript™ Standard mRNA Production System (Cellscript, USA) as previously described (29, 31 Table S1 ).
Embryo transfer. Embryonic day (E1.5) 2-cell embryos were transferred to the oviducts of pseudo-pregnant CD-1 females at day 0.5 (ie plugged females that had been mated with vasectomized males the previous night). Where appropriate, pups were delivered by Cesarian section and fostered by CD-1 females.
Genotyping. Genotyping was performed on ear-punch biopsies collected at weaning as described previously (3) were each collected into a PCR tube containing 0.5% (w/v) sarcosyl and flash-frozen in liquid nitrogen before being subjected to target PCR amplification with primer sequences as given in Supplementary Table S1 . Where appropriate, PCR products were gel-purified for sequence analysis.
Fluorescence imaging. Following oocyte injection, fluorescence of embryos was visualized on an IX71 (Olympus, Japan) microscope equipped with an AndroZyla cMOS camera and OptoLEP illumination system (Cairn Research, UK) as previously described (31) . Images were processed with Image J (imagej.nih.gov/ij/) or MetaMorph (Molecular Devices, USA) analysis software. Quantitative analyses subtracted background from subject area fluorescence intensities, which can produce negative results in beads experiments in which background levels from latex are lower than those of mII oocytes.
Statistical analysis.
All experiments were performed on at least two days. The number of samples (n) per experiment reflects oocyte or embryo survival after manipulation. All samples were randomly collected; that is, we did not knowingly select different classes of healthy oocytes or embryos except where stated and no data were selectively excluded.
Data analysis was performed with or without blinding. Statistical differences between pairs of data sets were analyzed by chi-squared or two-tailed unpaired t-test. Values of p < 0.05
were considered statistically significant. Table S1 ). Results of ear-punch genomic PCR for Sry are presented (upper)
Figure legends
for offspring generated when BOC had been included (+) or omitted. Internal reproductive organs are shown for wild type (wt) and sex-reversed adults. Scale bar, 5 mm. (B)
Developmental efficiency and phenotypes of offspring produced by ICSI with wt B6 sperm and oocytes as per (A), except that the mixture of three gRNAs targeted Tyr ( Supplementary   Table S1 ). The total number of offspring (total) is given with numbers exhibiting different coat-color phenotypes. Data reflect at least two experiments per target. (C) Offspring of (B) at 7 d. corresponding to the tg structure of (A), above] were injected with eGFP + sperm and a mixture of Cas9 cRNA (3,300 ng/μl) and eGFP gRNA (800 ng/μl). Also (rightmost), mII oocytes from pZP3-Cas9 K510B transgenic females (tg structure above) were injected with eGFP + sperm and a mixture of PylRS cRNA (600 ng/μl), Pyl tRNA (1,200 ng/μl) and eGFP gRNA (800 ng/μl) ( Supplementary Table S1 ) but no cRNA encoding Cas9 K510B . Incubation either omitted BOC (-) or included 1 mM BOC for 5 h (+).
